The management of CASPR2‐antibody conditions has received little attention to date.67, 68, 69 Our experience suggests that the ataxia and encephalopathy are usually responsive to similar therapeutic approaches as for patients with LGI1‐antibody encephalitis (Irani, Jacob, & Leite, 2017). The gene discussed is CNTNAP2; the disease is Encephalopathy.